O verwhelming evidence in numerous animal models indicates that lowering tissue temperature just a few degrees centigrade provides better protection against ischemia than any available drug. Hypothermia has proven to improve long-term outcomes in humans after cardiac arrest (1, 2) and neonatal asphyxia (3, 4) . In contrast, major trials of hypothermia for brain trauma (5), cerebral aneurysm surgery (6) , and acute myocardial infarction failed to demonstrate benefit-although limitations of each study preclude the conclusion that hypothermia is not helpful. This is particularly the case because most major outcome trials induced hypothermia relatively slowly and well after the insult.
Newer (faster) methods for reducing core temperature are now available (7) (8) (9) . However, it remains completely unclear how much hypothermia (if any) is optimal for various conditions, how long hypothermia should be maintained, and at what rate normothermia should be restored. Therapeutic hypothermia thus remains a subject of active investigation.
A difficulty associated with therapeutic hypothermia studies is that normal body temperature is jealously guarded by effective thermoregulatory defenses, which make it difficult to induce hypothermia. If these defenses are overcome by aggressive cooling, hypothermia comes at the cost of autonomic activation (10, 11) and considerable metabolic stress (12) . Therefore, a better approach is to pharmacologically impair thermoregulatory defenses. I thus review normal thermoregulatory control and discuss ways to induce a degree of thermal tolerance.
Normal Thermoregulation
Core body temperature is tightly regulated in most mammals, and in humans temperature is far more tightly regulatedinterestingly-than other "key" physiological parameters including blood pressure and heart rate. Temperature is sensed by the transient receptor potential (TRP) family of ion channels. Thermal TRPs are activated at distinct temperature thresholds and are typically expressed in sensory neurons. The subtype TRPV3 senses heat (13) , for example, whereas cold is sensed by TRPM8 (14) . Thermal information from the skin surface, peripheral tissues, core organs, and the neuraxis per se are integrated at various levels, finally arriving at the hypothalamus, which is the dominant thermoregulatory controller in mammals.
Thermoregulatory defenses can be grouped broadly into autonomic and behavioral responses. Behavioral defenses include putting on a sweater or opening a window, but also building shelter and central heating. Skin and core temperatures contribute comparably to central control of behavioral responses (15) . Overall, behavioral responses are far more powerful than autonomic defenses, and it is behavioral defenses that allow humans to live in the diverse environments that we do. However, they are also of little consequence in critically ill patients who have little ability to implement such defenses. Intensivecare patients thus depend on autonomic defenses and their caretakers.
The primary autonomic defenses against heat are sweating and active precapillary vasodilation; the primary autonomic defenses against cold are arteriovenous shunt vasoconstriction (16) and shivering (17) . In this review, I focus on cold defenses. Mean skin temperature contributes about 20% to control of autonomic responses to each major cold defense, with the remainder being from deeper tissues, the thermal core, and neuraxis (18, 19) .
Arteriovenous Shunt Vasomotion
Thermoregulatory arteriovenous shunts are specialized anastomoses linking arterioles with veins; they are largely restricted to fingers and toes. They are typ-ically about 100 m in diameter which is about ten times the size of capillaries. Because flow is proportionate to the fourth power of radius, shunts convey about 10,000 times as much blood as a comparable length of capillary. The threshold for shunt contraction is typically near 37°C and the gain is high; consequently, shunts usually transition linearly from being completely open to completely closed over just a couple of tenths of a degree centigrade (Fig. 1) .
Despite their limited anatomical distribution and number, arteriovenous shunts have a profound effect on core temperature. Thermoregulatory vasomotion is, in fact, the most commonly activated thermoregulatory defense-at least in cool environments such as hospitals. This is fortuitous because vasomotion is metabolically efficient, unlike shivering, and doesn't consume water as sweating does. Shunt constriction initially roughly halves fingertip heat loss, but the consequences of reduced peripheral blood flow that the arms and legs gradually cool. Metabolic heat, which is largely generated by deep organs, is thus constrained to the core thermal compartment (trunk and head) rather than being allowed to escape into peripheral tissues (arms and legs) and from there into the environment.
The second law of thermodynamics specifies that heat can only flow down a temperature gradient. It is thus apparent that there must normally be a gradient from core to peripheral tissues; otherwise, heat would accumulate in the core. In hospital environments, the gradient typically ranges from 2°C to 4°C (20) . The smaller gradient occurs when arteriovenous shunts are open and heat flows readily from the core to peripheral tissues, and from there is dissipated to the environment. In contrast, the larger gradient occurs when shunts are closed and metabolic heat is preserved in the core. Thermoregulatory vasomotion thus protects core temperature by varying peripheral tissue temperature and heat content; a corollary is that mammalian thermoregulation is mostly based on core temperature rather than body-heat content and that peripheral tissues are used to buffer the core from environmental perturbations.
Shivering
Shivering is characterized by involuntary oscillatory skeletal muscular activity. On a local level, movement is uncoordinated as reflected by a rapid (i.e., 250 Hz) electromyographic activity (21) . However, there is an overall 4 -8 cycle/min "waxingand-waning" activity that is clinically apparent during intense shivering (22) .
Efferent signals mediating shivering descend from the preoptic region of the hypothalamus to the medial forebrain bundle. The response is probably mediated by a central descending shivering pathway, although explicit experimental evidence is lacking. Spinal alpha-motor neurons and their axons are the final common path for both coordinated movement and shivering. During continued cold stimulation of the skin or the spinal cord, motor neurons are recruited in sequence of increasing size, starting with the small gamma motor neurons, followed by the small tonic alpha motor neurons, and finally, the larger phasic alpha motor neurons.
The threshold for shivering is typically a degree less than the vasoconstriction threshold (23) . Shivering is thus a "last resort" response, and appropriately so because it is metabolically inefficient. Furthermore, shivering is even less effective than may be expected on the basis of the increase in metabolic rate because much of the heat is generated by the large muscles in the legs, but is then dissipated to the environment rather than being retained in the core as would be heat generated by truncal organs and the brain.
The gain of shivering is not as high as it is for vasoconstriction, with the transition from no activity to maximum shivering intensity typically occurring over a range of about 1°C (24) . Although shivering can briefly augment metabolic rate by a factor of four or more, sustained shivering only doubles the basal metabolic rate even in young fit subjects. The increase in elderly subjects is considerably less (25) .
Interthreshold Range
Each thermoregulatory defense can be characterized by its threshold (triggering core temperature), gain (incremental response intensity, once triggered), and maximum intensity (response to supramaximal thermal stimulation). Body temperature is normally maintained between the sweating and vasoconstriction thresholds, temperatures that define the interthreshold range (also referred to as the "null zone"). Onset of sweating thus usually defines the upper boundary of normal body temperature and shunt vasoconstriction defines the lower boundary.
Typically, the interthreshold range is only a few tenths of a degree centigrade ( Fig. 2) (23) . It is likely that temperatures within this range are accurately sensed, but simply do not trigger thermoregulatory responses. Teleologically, this is reasonable because it would be disruptive to respond to tiny thermal deviations that are of no physiological consequence.
Under normal circumstances, thermoregulatory control can thus be roughly modeled as a discrete "setpoint." In this model, temperature is regulated like a home thermostat in which heating or air conditioning is either on or off. That this model doesn't account for the interthreshold range or null zone is normally of little consequence; but as we shall see below, the model fails completely in the context of drugs that impair thermoregulatory control.
Circadian Rhythm
Normal core temperature in humans averages about 37°C. Nearly all mammals have a similar average core temperature, although smaller species are generally slightly warmer than larger ones. Interestingly, even poikilothermic ("coldblooded") species maintain temperatures near 37°C using behavioral responses when a variety of ambient temperature options are provided.
There is a nearly 1°C sinusoidal circadian variation around this temperature with the maximum occurring midafternoon and the minimum 12 hrs later (26) . It is interesting that core temperature, at any given time, is regulated to within just a few tenths of a degree centigrade (23) , but that the daily variation is much higher (27) . This is especially surprising because animal studies indicate that as little as 1°C of hypothermia protects against tissue ischemia (28) .
Thermoregulation in Critically Ill Patients
Even during illness, core body temperature is usually well maintained. Nonetheless, serious diseases may provoke hypothermia or hyperthermia. By far the most common thermal perturbation is fever.
Hyperthermia and Fever Mechanisms
An increase in core temperature above 38°C is abnormal and defines hyperthermia. Increases in body temperature may be controlled (29) or uncontrolled (30) . Uncontrolled increases result from thermoregulatory failure, environmental stress that overcomes thermoregulatory control, or excessive heat production. Thermoregulatory failure can be central (i.e., anesthetic drugs or severe brain injury) or peripheral (i.e., drugs such as atropine, vasodilators, and muscle relaxants that prevent sweating, vasoconstriction, or shivering). The classic example of environmentally induced hyperthermia is heat stroke, in which extreme ambient temperature combines with dehydration and limits sweating. The most extreme example of excessive heat production is malignant hyperthermia, although excessive physical activity can also provoke dangerous degrees of hyperthermia (Table 1) .
A controlled increase, fever, results when the hypothalamus generates thermoregulatory responses such as vasoconstriction and shivering-and does so to a specific temperature without regard to the ambient environment. A characteristic of fever is thus that it synchronously increases the sweating and vasoconstriction thresholds; the thermoregulatory setpoint is thus elevated, but the precision of thermoregulatory control is well maintained (Fig. 3) .
Fever is mediated by exogenous or endogenous pyrogens that increase the body-temperature target in the hypothalamus (31) . Fever is mediated by soluble "endogenous pyrogens," cytokines that induce fever, which are released in response to immune activation. Various drugs can trigger release of cytokines (Table 2) . How cytokines interact with the hypothalamus remains unclear. However, they are believed to either cross the blood-brain barrier by facilitated transport mechanisms (32) , diffuse into areas of the brain where there is no blood-brain barrier (33) , or interact with peripheral neural components of the immune system to signal the hypothalamus to increase the thermal setpoint (34) . There is evidence to support each mechanism, and it seems likely that each contributes to some extent in various circumstances. 
Extremes of Age
Infants, children, and adults maintain comparable core temperatures. However, infants rely on nonshivering thermogenesis rather than shivering (35) . Even slightly premature infants can double oxygen consumption (and thus metabolic heat production) in response to a cool environment (36) . However, after about a year of age, humans consistently use the same set of autonomic responses.
Thermoregulatory is well preserved in the elderly. But after the age of about 80 yrs, the threshold for shivering is reduced about 1°C (Fig. 4) (37) . However, this result was observed in surgical patients and may thus overestimate thermoregulatory impairment in the general population. The vasoconstriction threshold also appears to be reduced about 1°C in the elderly (38) .
Paralysis
Pharmacological paralysis obviously stops shivering. However, paralysis only slightly reduces development of fever in response to pyrogen administration in volunteers (39) . This result suggests that paralysis per se may not help induce therapeutic hypothermia.
A further difficulty with depending on paralysis for induction of hypothermia is that paralysis per se does not prevent the fairly substantial autonomic activation associated with reductions in core temperature below the vasoconstriction threshold (10, 11, 40) . Paralysis should thus not be used as a substitute for pharmacological impairment of thermoregulatory defenses, any more than it should be used as a substitute for adequate sedation in critically ill patients.
More importantly, though, paralysis is not indicated for most patients likely to benefit from therapeutic hypothermia, once patients are paralyzed-and thus mechanically ventilated-it is easy to provide sufficient medication to blunt thermoregulatory defenses. The difficulty, as described below, is to induce thermal tolerance without provoking respiratory depression or other serious side effects.
Thermoregulatory Consequences of Therapeutic Hypothermia
In the context of deliberate core cooling, there are two problems with thermoregulatory defenses: a) vasoconstriction and shivering are each effective, thus slowing onset of hypothermia; and b) each activates autonomic and hemodynamic responses that may be harmful, especially in the fragile patients most likely to benefit from therapeutic hypothermia.
Vasoconstriction and Shivering Slow Peripheral-to-Core Heat Transfer
Under the best of circumstances, surface cooling in adults is relatively slow because heat must be extracted from peripheral tissues before core temperature decreases. Thermoregulatory vasoconstriction slows the process yet more; after all, the teleological purpose of thermoregulatory vasoconstriction is to constrain metabolic heat to the core thermal compartment and to limit dissipation of heat to the environment. It is effective in both regards, and the consequence is that surface cooling (and warming) is less effective than may be expected in vasoconstricted patients (41, 42) .
One way to circumvent this problem is to anesthetize patients. Most general anesthetics produce substantial arteriolar dilation. Consequently, surface warming (43) and cooling (44) remains effective whether or not arteriovenous shunts are constricted during anesthesia. In contrast, surface warming is less effective in constricted than dilated subjects after anesthesia (41, 42) . Of course, general anesthesia is rarely a practical approach to induction of therapeutic hypothermia.
A better approach is direct core cooling using heat-exchanging endovascular catheters. These systems circulate water through thin-walled catheters that are inserted into major vessels. Not only are heat-extraction rates high, but heat is extracted directly from the core and is thus not impaired by thermoregulatory vasoconstriction. Consequently, heat exchange is rapid, independent of patients' vasomotor status. Infusion of cold intravenous fluids (i.e., Ϸ4°C) is another option, with each liter initially reducing core temperature by about 0.8°C (20) .
Autonomic and Hemodynamic Consequences of Cold Defenses
Even mild hypothermia (1°C-2°C) increases plasma norepinephrine concentrations by a factor of seven and provokes a hyperdynamic response in young, fit subjects (40) . The norepinephrine increase is much less (Ϸ40% in elderly surgical patients) (11); nonetheless perioperative hypothermia causes morbid myocardial outcomes (45) .
The consequence of autonomic activation and increased peripheral vascular resistance is that mild hypothermia The shivering thresholds in seven of ten patients aged more than 80 yrs was Ͻ35.5°C, whereas the threshold equaled or exceeded this value in all of the younger patients. Reproduced with permission from Vassilieff et al (37) .
increases blood pressure, with a compensatory reduction in heart rate ( Fig. 5) . With or without concomitant general anesthesia, mild hypothermia increases mean arterial pressure by about 10 mm Hg (46) . The factor-of-two increase in metabolic rate associated with sustained shivering is sufficient to complicate induction of therapeutic hypothermia (17) . For one thing, few clinical cooling systems remove heat at the rate it is generated by shivering. However, more importantly, shivering is metabolically stressful and associated with potentially harmful hypertension. There is thus a consensus that shivering cannot be permitted in patients being therapeutically cooled.
Blunting Thermoregulatory Defenses
The interthreshold range usually spans only a few tenths of a degree centigrade; the setpoint or center of this range is normally 37°C but varies on a circadian basis and is increased by fever. Even with severe illness, thermoregulatory control remains precise. Fortunately, drugs have been identified that blunt or profoundly impair body temperature control. Impairment is characterized by a widening of the interthreshold, sometime by a factor of ten or more. Some of these drugs also reduce the gain and/or maximum intensity of thermoregulatory defenses.
Physical Methods
Mean-skin temperature contributes 20% to control of autonomic cold defenses, (18, 19) and 50% to thermal comfort (15) . Consequently, a 4°C increase in mean-skin temperature reduces the vasoconstriction and shivering thresholds about a degree centigrade. The cutaneous contribution to central control is the ba- (47) reported that focal hand warming suppresses shivering in mildly hypothermic volunteers. The same group also reported that shivering can be suppressed by warming of the lower face combined with inhalation of heated and humidified air (48) . Others have also reported that facial warming reduces shivering, (49) as does radiant heating of the face and upper chest (50) . The difficulty, though, is that the face and arms are only a small portion of the total skin surface. As may be expected, isolated hand or face warming only trivially reduces the shivering threshold (51) . In contrast, warming much of the skin surface is effective (52).
As described above, direct core cooling is faster than surface approaches because extracted heat doesn't have to traverse peripheral tissues. However, an additional problem associated with surface cooling is that it inordinately cools the skin surface, which provokes profound thermal discomfort. An advantage of direct core heat exchange is thus that, unlike with surface cooling, the skin can be kept relatively warm during induction of hypothermia. Cutaneous warming improves thermal comfort without much decreasing the rate of core cooling.
General Anesthetics
All volatile anesthetics profoundly impair autonomic cold defenses, and of course simultaneously obliterate behavioral responses (53) (54) (55) (56) . Impairment is nonlinear, being disproportionately large at the high end of the clinical dose range. Interestingly, anesthetics have relatively little effect on sweating (53, 57) . Nonetheless, typical doses of volatile anesthetics increase the interthreshold range 10-to 20-fold to about 4°C. However, of course general anesthesia is rarely an option for patients likely to benefit from therapeutic hypothermia, and anesthesia can hardly be maintained for the day or two that may be required.
An exception is propofol, which is an excellent sedative and is often used to sedate critical care patients. Loss of consciousness with propofol typically occurs at a plasma concentration of 2 g/mL, with a concentration of 4 g/mL representing a full general anesthetic. Propofol linearly and synchronously reduces the vasoconstriction and shivering thresholds, reaching a shivering threshold of Ϸ35°C at a plasma concentration of 2 g/mL and a threshold of Ϸ34°C at a plasma concentration of 4 g/mL (Fig. 6 ) (58).
Opioids
Alfentanil, a pure -receptor agonist produces a linear and synchronous dosedependent reduction in the shivering threshold (59) . (Alfentanil also blunts fever [60, 61] .) However, it takes a plasma concentration of 300 ng/mL to reduce the shivering threshold to 34.3°C Ϯ 0.8°C. This is a high dose that is associated with considerable potential for respiratory depression. Alfentanil alone is thus insufficient for induction of therapeutic hypothermia.
Meperidine, which is also known as pethidine, uniquely among opioids, inhibits shivering twice as much as vasoconstriction at any given dose (62) . What causes the special antishivering action of meperidine remains unclear. However, it does not appear to be related to the drug's kappa opioid receptor activity nor its inhibition of cholinergic receptors (63) . Possibly, meperidine's special antishivering activity results from stimulation of central alpha-2B receptors (64) . However, whatever the reason, meperidine is one of the most effective antishivering drugs known and is frequently used for treatment of postoperative shivering (65) . Nonetheless, meperidine alone is not usually sufficient for induction of therapeutic hypothermia (66) .
Nonopioids
Clonidine (67) and dexmedetomidine (68), both central alpha-2 receptor agonists, are effective antishivering agents that comparably and linearly reduce the vasoconstriction and shivering thresholds. A plasma concentration of dexmedetomidine of 0.8 ng/mL, for example, reduces the shivering threshold to about 34°C. Clonidine is available intravenously in Europe and elsewhere, whereas intravenous dexmedetomidine is available in the United States. Both alpha agonists are frequently used for treatment of postoperative shivering and each is highly effective (65) . Central alpha agonists are known for bradycardia and hypotension; however, they do not cause respiratory depression. They are thus ideal candidates for combining with other antishivering drugs, especially opioids.
Nefopam is a centrally active analgesic; it is a benzoxazocine compound that does not possess opioid or nonsteroidal properties and does not cause respiratory depression. Nefopam reduces the shivering threshold while having almost no effect on sweating or vasoconstriction (69) . With the exception of muscle relaxants, this is a unique pattern. Plasma concentrations of Ϸ50 ng/mL reduce the shivering threshold to nearly 35°C. Nefopam alone, at least in this dose, is thus insufficiently potent for induction of therapeutic hypothermia. However, because nefopam provokes few side effects, higher doses can probably be used safely. Similarly, it would seem a good choice for combining with other antishivering agents.
Several other drugs have been evaluated and shown to produce little if any impairment of shivering. Ineffective drugs include ondansetron (a 5HT-3 antagonist used for prevention and treatment of nausea and vomiting), (70) magnesium sulfate, (71) and doxapram (effectively, a central dopamine agonist) (72) . Dantrolene is a peripherally acting skeletal muscle relaxant primary used for treatment of malignant hyperthermia crises. Dantrolene slightly reduces the shivering threshold, but decreases the gain of shivering about 60%. The potential for dantrolene as an antishivering agent seems limited given its cost, low efficacy, and potential for respiratory toxicity. Tramadol (73) and midazolam (74) both slightly reduce the setpoint without much altering precision of thermoregulatory control. Neither is sufficiently potent to contribute much to induction of therapeutic hypothermia.
Drug Combinations
Because dexmedetomidine and meperidine are each effective and have different major toxicities (bradycardia and respiratory depression, respectively), they make a logical combination. In fact, they work well together, additively decreasing the shivering threshold about 2°C to about 35°C (51) . Meperidine and nefopam have been tested and shown to interact additively (unpublished results).
One of the best combinations so far evaluated is buspirone and meperidine. Buspirone is a serotonin 1A partial agonist that does not cause respiratory depression. Alone, it only slightly reduces the shivering threshold, but when it is combined with meperidine the shivering threshold is synergistically reduced. That is, the shivering threshold with the combination is reduced more than would be expected based on the individual effects on each drug alone (75) . This approach to shivering control was used in a large trial of therapeutic hypothermia for acute myocardial infarction (76) .
Another highly effective additive combination is buspirone and dexmedetomidine (Fig. 7) (77) . This combination reduces the shivering threshold about 2.5°C to about 34°C without reducing the gain or maximum intensity of shivering.
Clinical Strategies
Thermoregulation is a fundamental and powerful physiological defense that normally tightly regulates core temperature. Vasoconstriction and shivering each impede core cooling. They are also associated with autonomic activation and hypertension, neither of which is likely to be well tolerated by patients who may benefit from hypothermia. There is thus a consensus that at least shivering must be prevented or treated during induction of therapeutic hypothermia.
Based on advanced age or serious illness, some patients will tolerate core temperature reduction without specific treatment. Because the skin surface contributes to thermoregulatory control (and especially thermal comfort), induction of hypothermia can be facilitated by combining gentle skin-surface warming with direct core cooling such as that provided by infusion of cold fluids or endovascular heat exchangers.
Most patients will require pharmacological induction of thermal tolerance. No single nonanesthetic sufficiently reduces the shivering threshold at doses that are generally tolerated in unintubated patients. Several drugs are thus best combined to produce adequately blunt thermoregulatory responses without provoking excessive toxicity. One effective combination is buspirone and meperidine because, unlike other combinations, buspirone and meperidine synergistically reduce the shivering threshold. The combination of buspirone and dexmedetomidine, although additive, is comparably effective while avoiding the respiratory depression associated with opioid administration.
